Mindmaze Therapeutics Drops 5.8% as Shares Trade Near CHF 0.15
Mindmaze Therapeutics Holdin drops 5.8% to CHF 0.15 as Swiss biopharma focuses on rare disease therapies; market cap CHF 24.3 m.
- MINDMAZE THERAPEUTICS HOLDIN
- Switzerland
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read